The Companies No One Appreciates

Interest in small cap stocks is dwindling on the part of buy-side funds., This is partly due to funds' need for liquidity. But last year's gain of over 50% by stocks of large pharmaceutical companies makes the smaller, riskier stocks even less attractive now. Portfolio manager Skip Klein of T. Rowe Price was a casualty of the relatively poor performance of small cap stocks.

Most buy-side funds are heavily invested in big-cap companies, some as much as 70%, because big-cap stocks offer solid growth, stability, and greater liquidity. The average biotech stock trades about 130,000 shares per day, while large-market caps like Merck & Co. Inc. turn over 5 million shares. But some aggressive fund managers, looking for higher-than-industry average growth rates, will put a disproportionate amount of their money in small, overlooked companies with exciting technologies, hoping to catch lightning in a bottle.

Over the last year or so, the phenomenal growth of Big Pharma stocks has turned this strategy on its head, making the low-risk play a high-growth strategy as well. Indeed,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Quotables: Pharma Leaders On The Month’s Hot Topics

 

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Scrip

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback